We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.96%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$783M
AUM Growth
+$86.9M
Cap. Flow
+$43.3M
Cap. Flow %
5.53%
Top 10 Hldgs %
30.88%
Holding
120
New
12
Increased
45
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$13.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.8M
3
GKOS icon
Glaukos
GKOS
+$11.5M
4
AGN
Allergan plc
AGN
+$11.2M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$14.2M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$13.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$11.6M
4
NVCR icon
NovoCure
NVCR
+$10.8M
5
BIIB icon
Biogen
BIIB
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Financials 1.39%
3 Technology 0.15%
4 Energy 0.13%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
51
Rigel Pharmaceuticals
RIGL
$750M
$5.97M 0.76%
235,000
+97,410
+71% +$2.37M
AERI
52
DELISTED
Aerie Pharmaceuticals
AERI
$5.88M 0.75%
120,932
+45,932
+61% +$2.51M
DXCM icon
53
DexCom
DXCM
$32B
$5.87M 0.75%
480,000
+62,480
+15% +$1.1M
MRK icon
54
Merck
MRK
$318B
$5.76M 0.74%
94,320
-52,400
-36% -$3.18M
XNCR icon
55
Xencor
XNCR
$1.55B
$5.73M 0.73%
250,000
-9,556
-4% -$212K
UHS icon
56
Universal Health Services
UHS
$10.5B
$5.55M 0.71%
50,000
– –
IOVA icon
57
Iovance Biotherapeutics
IOVA
$2.87B
$5.51M 0.7%
711,163
+61,163
+9% +$387K
WBA
58
DELISTED
Walgreens Boots Alliance
WBA
$5.41M 0.69%
70,000
-30,000
-30% -$2.4M
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.55B
$5.33M 0.68%
100,000
+64,427
+181% +$3.82M
ALNY icon
60
Alnylam Pharmaceuticals
ALNY
$29.3B
$5.03M 0.64%
42,793
-37,397
-47% -$3.19M
EPZM
61
DELISTED
Epizyme, Inc
EPZM
$4.5M 0.57%
236,293
-15,843
-6% -$242K
JUNO
62
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.49M 0.57%
+100,000
New +$3.41M
MGNX icon
63
MacroGenics
MGNX
$257M
$4.1M 0.52%
221,914
+46,914
+27% +$813K
OMCL icon
64
Omnicell
OMCL
$1.68B
$4.08M 0.52%
80,000
-14,231
-15% -$682K
RAD
65
DELISTED
Rite Aid Corporation
RAD
$4M 0.51%
101,950
+84,450
+483% +$4M
HCA icon
66
HCA Healthcare
HCA
$89.5B
$3.98M 0.51%
50,000
-44,707
-47% -$3.6M
NVO
67
Novo Nordisk
NVO
$209B
$3.85M 0.49%
+160,000
New +$3.62M
ACHN
68
DELISTED
Achillion Pharmaceuticals
ACHN
$3.82M 0.49%
850,000
+684,000
+412% +$3.04M
RDUS
69
DELISTED
Radius Health, Inc.
RDUS
$3.47M 0.44%
90,000
+15,000
+20% +$589K
SAGE
70
DELISTED
Sage Therapeutics
SAGE
$3.12M 0.4%
50,000
– –
KERX
71
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.84M 0.36%
400,000
-25,111
-6% -$181K
DERM
72
DELISTED
Dermira, Inc.
DERM
$2.7M 0.34%
+100,000
New +$2.62M
CHRS icon
73
Coherus Oncology
CHRS
$196M
$2.4M 0.31%
180,000
+11,128
+7% +$147K
ICPT
74
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.32M 0.3%
40,000
+36,992
+1,230% +$3.98M
CMRX
75
DELISTED
Chimerix, Inc.
CMRX
$2.1M 0.27%
400,000
– –
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rhenman & Partners Asset Management held 120 positions worth $783M, up 12% from $696M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $43.3M of net new capital in Q3 2017, opening 12 new positions and adding to 45 existing holdings. Its largest new stake was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Pfizer, an estimated $14.2M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2017 buy was Arena Pharmaceuticals Inc: 569,491 shares worth $14.5M.
  • Rhenman & Partners Asset Management added most to Vertex Pharmaceuticals in Q3 2017, an estimated $12.8M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2017 reduction was Pfizer, cutting an estimated $14.2M.
  • Rhenman & Partners Asset Management fully exited NeuroDerm Ltd. Ordinary Shares in Q3 2017, selling an estimated $13.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $783M portfolio in Q3 2017.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 26 in Q3 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $783M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.